Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06751329 · ClinicalTrials.gov registry record · Phase 1
A Study of DM002 in Patients With Advanced Solid Tumors
A Phase 1 study of Prostatic Neoplasms and Colorectal Neoplasms, sponsored by Xadcera Biopharmaceutical (Suzhou) Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 160
- Enrollment target
- 5
- Study locations
NCT06751329 is a Phase 1 study of Prostatic Neoplasms and Colorectal Neoplasms that is actively recruiting participants, run by Xadcera Biopharmaceutical (Suzhou) Co.. The registered enrollment target is 160 participants, below the 512-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (69% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT06751329, a Phase 1 study of Prostatic Neoplasms and Colorectal Neoplasms, is actively recruiting participants, sponsored by Xadcera Biopharmaceutical (Suzhou) Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 160 participants
- Enrollment target
- 5
- Study locations
Study Summary
The goal of study： The study has two parts: Part 1 Dose Escalation and Part 2 Dose Expansion. In Part 1, a few participants will receive the lowest dose of study drug. The study team will make sure it is safe and tolerated before enrolling new participants at a higher dose of study drug. There will be up to six or more dose levels of study drug tested (called cohorts). Which dose you receive will depend on how many participants have taken part in the study before you. The purpose of Part 1 of the study is to evaluate the safety of the study drug at different dose levels, to understand what your body does to the study drug, and to find the best dose of study drug in people who have advanced solid tumor cancers. In Part 2, participants will receive the best dose level that was determined in Part 1 of the study. The purpose of Part 2 of the study is to evaluate the safety of the study drug at the dose level determined in Part 1, to understand what your body does to the study drug, and to see how your cancer responds to the study drug. Participants will: Participants will have 17 or more visits to the study centre. This study has a screening phase of up to 28 days , and a treatment phase with cycles of 21 days each. Participants will also have an End of Treatment (EOT) visit 21 days after the final study drug treatment, and a Follow-up visit 30 days after the EOT visit . Participants will be contacted by telephone every 3 months after the Follow-up visit to check on the wellbeing and record any new anticancer therapy they may have started.
Conditions Studied
Interventions
- DRUG DM002
Study Locations (5)
New South Wales
- Scientia Clinical Research - Randwick
- Cancer Care Wollongong - Wollongong
Oklahoma
- University of Oklahoma Health Sciences Center - Oklahoma City
Texas
- The University of Texas, MD Anderson Cancer Center - Houston
South Australia
- Southern Oncology Clinical Research Unit - Adelaide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2025-02-17 |
| Est. Completion | 2028-04-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06751329
The ClinicalTrials.gov registry entry for NCT06751329 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 512-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (69% lower). The listed sponsor is Xadcera Biopharmaceutical (Suzhou) Co., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Prostatic Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which DM002 is the first listed.
NCT06751329 reports 5 study locations spanning 4 distinct geographic areas - top geographies include New South Wales, Oklahoma, Texas.
Frequently Asked Questions
What is clinical trial NCT06751329 about?
NCT06751329 is a clinical study titled "A Study of DM002 in Patients With Advanced Solid Tumors". The goal of study： The study has two parts: Part 1 Dose Escalation and Part 2 Dose Expansion. In Part 1, a few participants will receive the lowest dose of study drug. The study team will make sure it is safe and tolerated before enrolling new participants at a higher dose of study drug. There wil...
What is the current status of trial NCT06751329?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 160 participants. The study started on 2025-02-17. Estimated completion is 2028-04-18.
What conditions does trial NCT06751329 study?
This clinical trial studies the following conditions: Prostatic Neoplasms, Colorectal Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Solid Carcinoma.
What interventions are being tested in trial NCT06751329?
The interventions under investigation include: DM002 (DRUG).
Who is sponsoring clinical trial NCT06751329?
This trial is sponsored by Xadcera Biopharmaceutical (Suzhou) Co., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06751329 being conducted?
This trial has 5 study locations across Oklahoma, Texas, New South Wales, South Australia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostatic Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
-
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
RECRUITING · Phase 1
-
A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
RECRUITING · Phase 1
-
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
RECRUITING · Phase 1
-
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
RECRUITING · Phase 1
-
A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.